The World Leader in Corneal Remodeling

Corporate Overview

Achievements 2017 Plan

• First in Class Corneal Remodeling Platform

• The Only FDA Approved Cross-linking

• Commercial• 1500 Systems • 250,000 Treatments

• Expand Keratoconus and Refractive Markets

• Driving Towards Reimbursement

• 14 Clinical Studies• Epi-On Procedures• Refractive Applications

Corneal Remodeling with Cross-linking:

Primary Indications

Refractive CorrectionKeratoconus

Treat underlying

disease state

Eliminate the need for

glasses or contacts

KXL

Uniformly strengthen corneal

stroma to stabilize

PiXL

Selectively strengthen the

corneal stroma to reshape

Ind

ica

tio

nS

olu

tio

n

Proven Mechanism of Action

Keratoconus

• Progressive corneal irregularity due to

underlying stromal weakness

• Number one cause for corneal transplants

• Published data from 1986 indicates

302,000 eyes1

• Newer diagnostic methods enable earlier

and more accurate diagnosis

1. Kennedy RH, Bourne WM, Dyer JA. A 48-year clinical and

epidemiological study of keratoconus. Am J Ophthalmol. 1986;101:267–73

Normal Cornea

Keratoconus

-0.9

-0.6

-0.3

0

0.3

0.6

0.9

KC CXL KC Control

n=175

p<0.0001

-0.9

-0.6

-0.3

0

0.3

0.6

0.9-1.5

-1

-0.5

0

0.5

1

1.5

2

KC CXL KC Control

2.6D

Difference

n=205

p<0.0001

-2.0

-1.5

-1.0

-0.5

0

0.5

1.0

1.5

Progressive Keratoconus Corneal Ectasia

The Only FDA Approved Treatment for

Progressive Keratoconus and Corneal Ectasia

1.4D

Difference

Reimbursement

• Medically indicated treatment for orphan

disease (progressive keratoconus)

• Not an elective procedure

• Hundreds of patients awaiting

reimbursement to get treatment

• Set up reimbursement hub: ARCH

Superior Outcomes with Oxygen

UVA Light

(365nm)

+

Corneal

Collagen

Crosslinks (Covalent Bonds)

Riboflavin

+

Oxygen is critical to the underlying photochemical kinetic mechanisms of crosslinking

Oxygen

O2

PiXL: Photorefractive Intrastromal Cross-linkingNon-Invasive Zonal Strengthening to Induce Corneal Remodeling

European Epi-On PiXL Studies: Preliminary Clinical Results

0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

0.9

1

Baseline 1 Month

De

cim

al A

cu

ity

Mean Distance UCVA (n=13)

20/100

20/25

Refractive Correction

Low Myopia

• Largest population under 45 years

of age needing glasses

• Glasses and Contact Lens users

Presbyopia

• Loss of near focus

• Everyone above 45 years of Age

Potential

Future Indications

•Hyperopia

• Astigmatism

• Post IOL Correction

•Customized KC

- 0.75 to -1.25D >27M eyes

- 0.75 to -2.75D >62M eyes

US PiXL OpportunityMarket by Refractive Error

Corporate Overview

Achievements

• First in Class Corneal Remodeling Platform

• The Only FDA Approved Cross-linking

• Commercial

• 1500 Systems • 250,000 Treatments

2017 Plan

• Expand Keratoconus and Refractive Markets

• Driving Towards Reimbursement

• 14 Clinical Studies

• Epi-On Procedures• Refractive Applications

Solid Foundation

• Strong Management Team and Advisors

• Strong Investor Syndicate

• Strong Balance Sheet

Thank You

Visit Avedro at

Booth #: 637